Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03431974
Recruitment Status : Recruiting
First Posted : February 13, 2018
Last Update Posted : January 16, 2019
Sponsor:
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Syntrix Biosystems, Inc.

Brief Summary:
This study evaluates the treatment of psoriasis with aminopterin. Participants will be treated for 14 weeks with either aminopterin or placebo followed. The participants will not know if they are being treated with aminopterin or placebo.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: Aminopterin oral capsule Drug: Placebo oral capsule Phase 2

Detailed Description:
A Phase 2, multi-center, randomized, double-blind, placebo-controlled study enrolling subjects with moderate-to-severe psoriasis to investigate the safety and efficacy of LD-aminopterin (AMT) (3 mg (six 0.5 mg tablets). Forty-six subjects will be randomized to one of two parallel treatment arms: LD-AMT (3 mg) or placebo, in a 1:1 ratio. The endpoint analysis will include efficacy and safety. Randomized subjects will initially enter a 14-week treatment phase, followed by a 6-week post-treatment phase.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Over-encapsulated
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial to Establish the Efficacy and Safety of Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
Actual Study Start Date : November 1, 2018
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: Aminopterin oral capsule
LD-Aminopterin tablets (0.5 mg tablet) over-encapsulated, 3.0 mg (6 tablets) once orally each week for 14 weeks (14 doses).
Drug: Aminopterin oral capsule
anti-folate treatment

Placebo Comparator: Placebo oral capsule
Placebo capsules containing microcrystalline once orally each week for 14 weeks (14 doses).
Drug: Placebo oral capsule
Microcrystalline filled capsule to mimic capsule containing aminopterin tablets
Other Name: Placebo (for aminopterin)




Primary Outcome Measures :
  1. Psoriasis Area and Severity Index (PASI) (Efficacy) [ Time Frame: 98 days. ]

    As follows:

    1. Area of Involvement. Determine a score, from 0 to 6, for each body section (head, trunk, upper limbs, lower limbs) based on the percent of psoriasis skin involvement: 0=0%, 1=<10%, 2=10% to <30%, 3=30% to <50%, 4=50% to <70%, 5=70% to <90%, 6=90% to 100%.
    2. Severity of Involvement. Determine a score, from 0 to 4, for each body section (head, trunk, upper limbs, lower limbs), for the psoriatic skin severity of each of erythema, thickness, and scaling: 0=none, 1=slight, 2=moderate, 3=severe, 4=very severe. For each body section the three severity scores are summed.
    3. For each body section the product of the Area and Severity is determined.
    4. For each body section the product of line 3 is multiplied by an Area Factor (head=0.1, trunk=0.3, upper limbs=0.2, lower limbs=0.4).
    5. A PASI score is determined by summing the 4 body section products (line 4). The highest possible score=72; the lowest possible score=0. The higher the scores, the worse the psoriasis.

  2. Static Physician Global Assessment (sPGA) (Efficacy) [ Time Frame: 98 days. ]

    As follows:

    1. Induration. A score, from 0 to 5, based on: 0=No plaque elevation; 1= Minimal plaque elevation=0.25 mm; 2=Mild plaque elevation=0.5 mm; 3=Moderate plaque elevation=0.75 mm; 4=Marked plaque elevation=1.0 mm; 5=Severe plaque elevation>1.25 mm.
    2. Erythema. A score, from 0 to 5, based on: 0=No erythema, hyperpigmentation may be present; 1=Faint erythema; 2=Light red coloration; 3=Moderate red coloration; 4=Bright red coloration; 5=Dusky to deep red coloration.
    3. Scaling. A score, from 0 to 5, based on: 0= No scaling; 1=Minimal; occasional fine scale on<5% of the lesion; 2=Mild; fine scale predominates; 3=Moderate; coarse scale predominates; 4=Marked; thick, non-tenacious scale predominates; 5=Severe; very thick, tenacious scale predominates.
    4. The sPGA: Induration, Erythema, and Scaling scores are rounded to the nearest whole number and averaged. 0=Cleared; 1=Minimal; 2=Mild; 3=Moderate; 4=Marked; 5=Severe. Higher score indicates worse psoriasis.

  3. Analysis of Treatment Emergent Adverse Events [ Time Frame: 140 days. ]
    Analysis of treatment emergent adverse events to include incidence, severity, and relationship to study drug treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Be 18 years of age or older.
  2. Have a diagnosis of moderate-to-severe psoriasis for at least 6 months confirmed by a dermatologist, defined here as plaque-type psoriasis affecting a body surface area of >10% and a PASI of >10.
  3. Agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources during the study.
  4. Ability to understand and sign written informed consent.
  5. Heterosexually active men and women of childbearing potential must use two methods of contraception during the study (20 weeks) and for 90 days after study completion. The two methods of birth control may be used simultaneously in the same subject or simultaneously in both partners. The two birth control methods can be (a) 2 barrier methods or (b) a barrier method plus a hormonal method to prevent pregnancy.

    Barrier methods include: condom (female or male), copper intrauterine device, sponge, or spermicide.

    Hormonal Methods include: any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent, including oral, subcutaneous, intrauterine, or intramuscular agents.

  6. For pre-menopausal women, a negative pregnancy test, obtained within 1 week prior to first study drug dose and at study visits Week 0, Week 6, Week10, Week 14, and Week 20. If at any visit during the Treatment Phase (see Appendix A) a positive pregnancy test is returned, the subject will be discontinued from any further study drug.
  7. Negative serology for human immunodeficiency virus 1 and 2 (HIV1/2), hepatitis B and hepatitis C.
  8. The following screening laboratory blood tests must have the following values, or not clinically significant as determined by the PI and Medical Monitor: white blood cells (WBC) within normal limits (WNL); absolute neutrophil count > lower limit of normal; platelet count WNL; hemoglobin >10.0 g/dL; aspartate aminotransferase (AST) < 2.5 x the upper limit of normal.
  9. Adequate renal function: creatinine clearance estimated by Cockcroft-Gault formula >60 ml/min

Exclusion Criteria:

  1. Known history of hepatitis, HIV infection, interstitial lung disease.
  2. Greater than moderate alcohol consumption on a regular basis (moderate consumption for females is 1 drink or 1 glass of wine a day; for males is 2 drinks or 2 glasses of wine a day) and unwilling, or unable, to control consumption during the study period.
  3. Prior use of aminopterin (AMT).
  4. Use of these biologic treatments in the time frames specified:

    • Within 9 months of first study drug dose: ustekinumab (Stelara).
    • Within 12 weeks of first study drug dose: any experimental therapy for psoriasis or rheumatoid arthritis.
    • Within 8 weeks of first study drug dose: infliximab (Remicade), adalimumab (Humira).
    • Within 4 weeks of first study drug dose: etanercept (Enbrel).
    • Other biologic therapies will have discontinuation periods determined by 5x their half-life.
  5. Within 90 days prior to Day 0 and at any time while on study, the use of MTX.
  6. Within 4 weeks prior to randomization and at any time while on study, use of phototherapy (e.g., ultraviolet B (UVB), narrow band UVB, Goeckerman regimen, Ingram regimen, PUVA), systemic medications (e.g. acitretin, mycophenolate mofetil, tacrolimus/FK506, cyclosporine A, azathioprine, 6-thiogaunine, sulfasalazine, hydroyurea, calcitriol, any systemic immunosuppressants), lithium, or any treatments that could affect psoriasis or sPGA evaluations. Subjects are eligible 4 weeks after the last dose of any of the aforementioned treatments was received.
  7. Within 2 weeks prior to randomization and at any time while on study, use of any topical medications or treatments that could affect psoriasis evaluations (e.g., corticosteroids, anthralin, vitamin D3/calcitriol and analogues such calcipotriene and tacalcitol, synthetic retinoids such as tazarotene, coal tar, and keratolytics such as salicylic acid, lactic acid and urea including those contained in over-the-counter medicated shampoos). Subjects are eligible 2 weeks after the last dose of any of the aforementioned treatments was received.

    Note: Over-the-counter topical steroids will be permitted for use limited to the face, axilla, and/or genitalia, as needed. These topical medications should not be used within approximately 24 hours prior to study visits Day 0 and Day 98. Over-the-counter shampoos for the treatment of psoriasis of the scalp are also permitted.

  8. Use of emollients on the morning of the first (Week 0) study visit.
  9. Within 2 weeks prior to Study Day 0, or on Study Day 0, or at any time during the study, use of any of the following medications that may result in drug/drug interactions with AMT: trimethoprim with or without sulfamethoxazole; sulfonamides; sulfonylureas; pyrimethamine; triamethamine; salicylates; non-steroidal anti-inflammatory (NSAID) drugs including ibuprofen; dipyridamole; colchicine; probenecid; aminoglycosides; theophylline; phenytoin; and folinic acid (i.e., leucovorin).
  10. Known concurrent malignancy except basal or squamous cell skin carcinoma, or cervical carcinoma in situ.
  11. Concurrent participation in another clinical trial involving experimental treatment within 30 days of Study Day 0.
  12. Current and uncontrolled infection, cardiovascular, renal, pulmonary, hepatic or GI conditions that will interfere with the conduct of the trial or pose a morbid risk.
  13. Investigator's opinion that a concurrent disease or condition impairs the subject's ability to complete the trial: includes psychological, familial, sociological, geographical or medical conditions.
  14. Breast-feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03431974


Contacts
Layout table for location contacts
Contact: Stuart Kahn, MD 253-833-8009 ext 31 skahn@syntrixbio.com

Locations
Layout table for location information
United States, Arizona
Investigate MD Recruiting
Scottsdale, Arizona, United States, 85255
Contact: Jenna Sanford    480-398-1550    investigatemd@gmail.com   
Principal Investigator: Brenda LaTowsky, MD         
United States, Washington
Premier Clinical Research Recruiting
Spokane, Washington, United States, 99202
Contact: Kim Walter, CCRC    509-343-3710 ext 1135    KWalter@premierclinicalresearch.com   
Contact: Kristyn R Aalto    509-343-3710 ext 1152    kaalto@premierclinicalresearch.com   
Principal Investigator: Tiffany S Hanf, M.D.         
Sub-Investigator: William P Werschler, M.D.         
Sponsors and Collaborators
Syntrix Biosystems, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Layout table for investigator information
Study Director: Stuart Kahn, MD Syntrix Biosystems

Publications of Results:
Layout table for additonal information
Responsible Party: Syntrix Biosystems, Inc.
ClinicalTrials.gov Identifier: NCT03431974     History of Changes
Other Study ID Numbers: AMT-PSO-201
5U44AI114473 ( U.S. NIH Grant/Contract )
First Posted: February 13, 2018    Key Record Dates
Last Update Posted: January 16, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Syntrix Biosystems, Inc.:
Anti-folate

Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Aminopterin
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action